Payment overview · 2025
General Payments
$290.75
14 reported records · 10 companies
Healthcare provider profile · identity verified
Khyber Khan, MD
Allopathic & Osteopathic Physicians|Family Medicine · GLENVILLE, NY · NPI 1902113699
Verified facts
What the public records show
CMS Open Payments records show Khyber Khan, MD received $290.75 in general payments during 2025 across 14 reported records.
Renalytix AI, Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $62.80 | 21.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.99 | 13.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $31.60 | 10.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.53 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.57 | 9.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.98 | 8.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.64 | 7.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.86 | 7.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.45 | 6.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.33 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.75 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $62.80 | 4 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $31.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 367 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 308 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 291 | 39 |
| Metformin Hcl | Metformin Hcl | 279 | 69 |
| Omeprazole | Omeprazole | 271 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 77 |
| Famotidine | Famotidine | 228 | 70 |
| Lisinopril | Lisinopril | 226 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 45 |
| Losartan Potassium | Losartan Potassium | 182 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 30 |
| Alprazolam | Alprazolam | 146 | 25 |
| Gabapentin | Gabapentin | 141 | 37 |
| Pregabalin | Pregabalin | 140 | 27 |
| Trazodone Hcl | Trazodone Hcl | 132 | 34 |
| Prednisone | Prednisone | 131 | 77 |
| Furosemide | Furosemide | 126 | 32 |
| Tramadol Hcl | Tramadol Hcl | 125 | 44 |
| Finasteride | Finasteride | 120 | 28 |
| Allopurinol | Allopurinol | 116 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 34 |
| Simvastatin | Simvastatin | 116 | 28 |
| Sertraline Hcl | Sertraline Hcl | 111 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 24 |
| Ozempic | Semaglutide | 108 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 16 |
| Diazepam | Diazepam | 88 | 16 |
| Mounjaro | Tirzepatide | 88 | suppressed |
| Potassium Chloride | Potassium Chloride | 87 | 28 |
| Clonazepam | Clonazepam | 83 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | 13 |
| Eliquis | Apixaban | 78 | 19 |
| Buspirone Hcl | Buspirone Hcl | 69 | 12 |
| Ezetimibe | Ezetimibe | 69 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 14 |
| Montelukast Sodium | Montelukast Sodium | 69 | 18 |
| Cephalexin | Cephalexin | 67 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 17 |
| Azelastine Hcl | Azelastine Hcl | 63 | 26 |
| Bupropion Xl | Bupropion Hcl | 61 | 12 |
| Synthroid | Levothyroxine Sodium | 60 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 16 |
| Meloxicam | Meloxicam | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 15 |
| Trulicity | Dulaglutide | 55 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Atenolol | Atenolol | 50 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 50 | 14 |
| Azithromycin | Azithromycin | 49 | 32 |
| Repaglinide | Repaglinide | 49 | 14 |
| Valsartan | Valsartan | 49 | suppressed |
| Irbesartan | Irbesartan | 48 | 16 |
| Novolog Flexpen | Insulin Aspart | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 11 |
| Jardiance | Empagliflozin | 46 | 12 |
| Fenofibrate | Fenofibrate | 43 | 12 |
| Fluconazole | Fluconazole | 42 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 15 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Lovastatin | Lovastatin | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 38 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Nystatin | Nystatin | 38 | 14 |
| Glipizide Er | Glipizide | 37 | 12 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | 12 |
| Alendronate Sodium | Alendronate Sodium | 35 | 13 |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Carisoprodol | Carisoprodol | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Glipizide | Glipizide | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 11 |
| Torsemide | Torsemide | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 12 |
| Meclizine Hcl | Meclizine Hcl | 22 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Zaleplon | Zaleplon | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Testosterone | Testosterone | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ramelteon | Ramelteon | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.75 · 14 records | Renalytix AI, Inc. | ABRYSVO, CAPVAXIVE, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, General - Pain Management, JOURNAVX, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error